The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Inclusion Criteria: * Diagnosis of noninfectious intermediate, posterior or panuveitis of at least 3 months duration * Treatment with greater than or equal to 20 mg/day of Prednisone at baseline or immunosuppressive drug score of greater than or equal to 5 at baseline * BCVA by ETDRS protocol better than or equal to 20/200 * Intraocular pressure of 24 mmHg or less * Anterior chamber cells and vitreous haze of less than or equal to 1 * Male or females, aged 12 or greater, body weight of 40 kg or greater Exclusion Criteria: * Prior treatment with Retisert * Primary diagnosis of anterior uveitis, uveitis of infectious etiology or Behcet's disease * Pregnancy or breast-feeding * Increase in systemic immunosuppressive treatment regimen within 6 weeks before baseline